Enterprise Value
-5.711M
Cash
10.58M
Avg Qtr Burn
-2.754M
Short % of Float
1.84%
Insider Ownership
3.98%
Institutional Own.
45.08%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INOpulse Details Interstitial lung disease, Pulmonary hypertension | Failed Discontinued | |
INOpulse Details Chronic obstructive pulmonary disease, Pulmonary hypertension, Heart disease, Heart failure | Failed Discontinued | |
INOpulse Details Sarcoidosis, Pulmonary hypertension | Failed Discontinued | |
INOpulse® Details COVID-19 | Failed Discontinued |